PDF) The "dual-pathway" strategy after acute coronary syndrome: Rivaroxaban and antiplatelet agents in the ATLAS ACS 2-TIMI 51 trial
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome | NEJM
Frontiers | Low Dose Rivaroxaban for Atherosclerotic Cardiovascular Diseases: A Systematic Review and Meta-analysis
ATLAS ACS2-TIMI 51 – TIMI STUDY GROUP
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial - The Lancet
Results of the ATLAS ACS-TIMI 46 Study Published in The Lancet - wikidoc
ATLAS ACS 2-TIMI 51: Primary Efficacy Endpoint CV Death / MI / Stroke - NOACs in Post-ACS Setting - Anticoagulation in the Post-Warfarin Era: Where Are We Today?
NOACS: Emerging data in ACS/IHD - ppt download
ATLAS ACS2-TIMI 51 – TIMI STUDY GROUP
ATLAS ACS-TIMI 46 – TIMI STUDY GROUP
Thrombin and Myocardial Infarction: Implications for Oral Anticoagulation (Transcript)
ATLAS ACS 2-TIMI 51: Safety Endpoints - NOACs in Post-ACS Setting - Anticoagulation in the Post-Warfarin Era: Where Are We Today?
Dia 1
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome | NEJM
![PDF] Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/28cdc9f7ebf4529018a7c9ea31d2282fb44f4c13/4-Figure2-1.png "PDF] Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. | Semantic Scholar")
PDF] Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. | Semantic Scholar
60004-2.fp.png "RIVAROXABAN REDUCES SPONTANEOUS AND LARGE MYOCARDIAL INFARCTIONS: FINDINGS FROM THE ATLAS ACS 2 – TIMI 51 TRIAL | Journal of the American College of Cardiology")
RIVAROXABAN REDUCES SPONTANEOUS AND LARGE MYOCARDIAL INFARCTIONS: FINDINGS FROM THE ATLAS ACS 2 – TIMI 51 TRIAL | Journal of the American College of Cardiology
Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51 | tctmd.com
ATLAS ACS 2-TIMI 51: Statistical Analysis Pre-specified Primary Efficacy Analysis - NOACs in Post-ACS Setting - Anticoagulation in the Post-Warfarin Era: Where Are We Today?
atlas acs 2
ATLAS ACS 2-TIMI 51 - NOACs in Post-ACS Setting - Anticoagulation in the Post-Warfarin Era: Where Are We Today?
Rivaroxaban in Patients Stabilized After a ST-Segment Elevation Myocardial Infarction: Results From the ATLAS ACS-2–TIMI-51 Trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary
![The ATLAS ACS 2-TIMI 51 trial [11] | Download Table](https://www.researchgate.net/publication/262845959/figure/tbl1/AS:670449130295299@1536858937293/The-ATLAS-ACS-2-TIMI-51-trial-11.png "The ATLAS ACS 2-TIMI 51 trial [11] | Download Table")
The ATLAS ACS 2-TIMI 51 trial [11] | Download Table
